Arginine deiminase: A potential inhibitor of angiogenesis and tumour growth

I. S. Park, S. W. Kang, Y. J. Shin, K. Y. Chae, M. O. Park, M. Y. Kim, D. N. Wheatley, Bon Hong Min

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Hydrolysis of plasma arginine to citrulline by arginine deiminase (ADI) was recently shown to suppress lipopolysaccharide-induced nitric oxide (NO) synthesis. Since arginine is the precursor of NO, and the latter modulates angiogenesis, we explored whether ADI treatment significantly affected tube-like (capillary) formation of human umbilical vein endothelial cells. Inhibition occurred in a dose-dependent manner, both in the chorioallantoic membrane and the murine Matrigel plug assay. Inhibition of angiogenesis by ADI was reversed when a surplus of exogenous arginine was provided, indicating that its antiangiogenic effect is primarily due to arginine depletion, although other pathways of interference are not entirely excluded. Arginine deiminase is also shown to be as a potent inhibitor of tumour growth in vitro as in vivo, being effective at nanogram quantities per millilitre in CHO and HeLa cells. Thus, it could be highly beneficial in cancer therapy because of its two-pronged attack as both an antiproliferative and an antiangiogenic agent.

Original languageEnglish
Pages (from-to)907-914
Number of pages8
JournalBritish Journal of Cancer
Volume89
Issue number5
DOIs
Publication statusPublished - 2003 Sep 1

Keywords

  • Antiangiogenic
  • Antiproliferative
  • Arginine
  • Arginine deiminase
  • Citrulline
  • NO

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Arginine deiminase: A potential inhibitor of angiogenesis and tumour growth'. Together they form a unique fingerprint.

  • Cite this

    Park, I. S., Kang, S. W., Shin, Y. J., Chae, K. Y., Park, M. O., Kim, M. Y., Wheatley, D. N., & Min, B. H. (2003). Arginine deiminase: A potential inhibitor of angiogenesis and tumour growth. British Journal of Cancer, 89(5), 907-914. https://doi.org/10.1038/sj.bjc.6601181